^
    Back
    Association details:
    Biomarker:PLK2 underexpression
    Cancer:Glioblastoma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Exp Clin Cancer Res
    Title:

    Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling

    Published date:
    11/11/2020
    Excerpt:
    ...reduced PLK2 expression implied poor prognosis and TMZ resistance in GBM patients.
    DOI:
    10.1186/s13046-020-01750-4